{"schema_version":"secwatch.filing_event.v1","accession":"0000012208-24-000050","form_type":"8-K","ticker":"BIO","cik":"0000012208","company_name":"BIO-RAD LABORATORIES, INC.","filed_at":"2024-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.379472+00:00","generated_at":"2026-05-31T13:41:06.523388+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Bio-Rad Q2 net sales down 6.3% YoY; Life Science weak, Diagnostics up 2.1%; board adds $500M buyback","bullets":["Q2 net sales $638.5M, -6.3% YoY; Life Science $250.5M (-16.5%), Diagnostics $387.9M (+2.1%).","Gross margin improved to 55.6% from 53.2%; operating income $101.5M vs $89.6M YoY.","Net loss $2,165.5M ($76.26 diluted EPS) mainly due to non-cash fair value adjustment of Sartorius investment.","CEO expects more modest pace of market recovery than originally anticipated.","Board authorized additional $500M share repurchase; total available ~$578M as of July 31, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000012208-24-000050","json":"https://secwatch.observer/filing/0000012208-24-000050.json","markdown":"https://secwatch.observer/filing/0000012208-24-000050.md","text":"https://secwatch.observer/filing/0000012208-24-000050.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/12208/000001220824000050/0000012208-24-000050-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/12208/000001220824000050/bio-20240729.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T13:41:06.523388+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}